Results Update
For
QE31/7/2014, Yinson's net profit increased by 2% q-o-q or 200% y-o-y to RM31 million while revenue was mixed- down 5% q-o-q but rose 23% y-o-y to RM281 million. The bottom-line improved by RM0.4 million q-o-q due to better segmental results (albeit lower revenue) and lower finance costs, which more than offset higher tax charge and lower share of results from associate and JVs. When compared to the same quarter last year, Yinson's bottom-line improved by RM20 million due to higher segmental results of RM20 million (of which RM16 million was contributed by the Marine division) and higher share of results from associate and JVs, which more than offset the increase in finance costs and tax charges.
Table 1: Yinson's last 8 quarterly results
Chart 1: Yinson's last 28 quarterly results
Valuation
Yinson
(RM3.38 last Friday) is now trading at a trailing PE of 30.4 times (based
on last 4 quarters' EPS of 11.07 sen). At this multiple, Yinson is deemed fully valued.
Technical Outlook
Yinson
is in an uptrend, with support at RM3.00 (using the 20-week SMA line as a proxy for uptrend line).
Chart 2: Yinson's weekly chart as at Sep 26, 20114 (Source: Tadesignum)
Conclusion
Despite good financial performance & positive
technical outlook, it is not easy to make a case to buy Yinson due to its high valuation. For now, I would rate it a HOLD.
Note:
In
addition to the disclaimer in the preamble to my blog, I hereby confirm
that I do not have any relevant interest in, or any interest in
the acquisition or disposal of,Yinson.
4 comments:
Alex any comment on why DSONIC keeps dropping?
Hi Ks
DSONIC has broken below two horizontal supports at RM1.70 & RM1.60.
The latest breakdown is quite significant because the next support is at RM1.20-1.30.
Unless we see a quick recovery, DSONIC could continue to slide.
Hi Alex,
Esceram looks interesting. What do you think?
Thanks.
Hi lai
Esceram has broken above its horizontal line at RM0.15. Its immediate resistance is at RM0.20.
Esceram's financial performance for the past 10 years is a big yawn. And, that explains its meandering share price movement.
In the current market where any stock can be "talked up", I don't rule out Esceram going higher. You do well to treat it as just a play.
Post a Comment